한글목차

트라스투주맙 바이오시밀러의 동향과 전망

세계 트라스투주맙 바이오시밀러 시장의 미래는 병원 약국 시장과 온라인 약국 시장에 기회가 있어 유망합니다. 세계 트라스투주맙 바이오시밀러 시장은 2024년부터 2030년까지 28.5%의 연평균 복합 성장률(CAGR)을 나타낼 전망입니다. 이 시장의 주요 촉진요인은 위암 및 유방암 발병률 증가와 바이오시밀러 의약품 파이프라인의 확장입니다.

• Lucintel의 예측에 따르면, 제품 카테고리에서 오기브리는 예측 기간 동안 가장 높은 성장률을 보일 것으로 예상됩니다.
• 판매 채널별로는 병원 약국이 예측 기간 동안 높은 성장세를 보일 것으로 예상됩니다.
• 지역별로는 북미가 예측 기간 동안 가장 규모가 큰 지역으로 남을 것으로 보입니다.

트라스투주맙 바이오시밀러 시장의 전략적 성장 기회

트라스투주맙 바이오시밀러 시장의 주요 전략적 성장 기회는 다음과 같습니다.

• 신흥 시장에서의 확장: 신흥 시장에서의 확장: 신흥 시장에서 트라스투주맙 바이오시밀러의 가용성 확대는 큰 성장 기회를 가져옵니다. 고가의 생물학적 제제에 대한 접근성이 제한되어 있는 이들 지역에서는 저비용 대안이 매우 중요합니다.
• 각국의 의료 시스템 통합: 트라스투주맙 바이오시밀러를 각국의 의료비 상환 시스템에 통합함으로써 채택을 촉진할 수 있습니다. 이 전략은 환자의 접근성을 높이고 치료 비용을 낮추기 위해 필수적입니다.
• 암 치료 프로토콜: 트라스투주맙 바이오시밀러의 수용이 확대됨에 따라 표준 암 치료 프로토콜에 대한 통합이 확대되고 있습니다. 이를 통해 트라스투주맙 바이오시밀러 제제가 더 많은 환자군에서 사용될 수 있게 될 것입니다.
• 혁신적 가격 전략: '가치 기반 가격 책정'(value-based pricing)과 같은 혁신적인 가격 책정 모델을 개발하여 시장 경쟁력을 높일 수 있습니다. 이 접근법은 비용과 치료 결과를 일치시켜 의료 제공업체와 지불자 모두에게 어필할 수 있습니다.
• 전략적 파트너십: 바이오시밀러 개발업체와 대형 제약사와의 전략적 파트너십 구축은 시장 침투를 가속화할 수 있습니다. 이러한 파트너십은 규제 환경을 극복하고 유통을 확대하는 데 매우 중요합니다.

결론적으로, 이러한 성장 기회는 트라스투주맙 바이오시밀러 시장의 확장을 촉진하고, 다양한 지역과 의료 시스템에서 암 치료를 보다 쉽고 저렴하게 이용할 수 있도록 하고 있습니다.

트라스투주맙 바이오시밀러 시장 활성화 요인 및 과제

트라스투주맙 바이오시밀러 시장은 기술적, 경제적, 규제적 요인을 포함한 다양한 시장 성장 촉진요인 및 과제에 의해 형성되고 있습니다. 이러한 요소들은 총체적으로 시장 성장과 바이오시밀러 치료에 대한 접근성에 영향을 미칩니다.

트라스투주맙 바이오시밀러 시장 성장 촉진요인

1. 비용 절감: 바이오시밀러 제제는 오리지널 제제에 비해 저렴한 비용으로 특히 비용에 민감한 시장에서 채택이 확대되고 있습니다.

2. 특허만료: 오리지널 바이오의약품의 특허만료로 인해 바이오시밀러에 시장이 개방되고, 경쟁이 치열해져 가격이 하락할 것입니다.

3. 규제 지원: 주요 시장의 유리한 규제 프레임워크가 바이오시밀러의 승인과 채택을 가속화하고 있습니다.

4. 암 발병률 증가: 전 세계 암 발병률 증가로 인해 저렴한 치료제에 대한 수요가 증가하면서 바이오시밀러 시장의 성장을 견인하고 있습니다.

5.생명공학의 발전: 생명공학 공정의 혁신으로 바이오시밀러의 생산과 품질이 향상되고 경쟁력이 강화되고 있습니다.

트라스투주맙 바이오시밀러 시장에서의 과제:

1. 시장 수용: 바이오시밀러에 대한 의사와 환자의 신뢰를 얻는 것은 여전히 과제이며, 광범위한 교육과 임상 데이터가 필요합니다.

2. 규제의 복잡성: 바이오시밀러 개발 기업에게 지역별로 상이한 규제 요건에 대응하는 것은 복잡하고 시간이 많이 걸립니다.

3. 가격 압력: 바이오시밀러 간의 치열한 경쟁은 가격을 낮추고 수익성과 시장의 지속가능성에 영향을 미칠 수 있습니다.

결론적으로, 트러스투주맙 바이오시밀러 시장을 형성하는 데 있어 이러한 촉진요인과 도전 요인의 상호 작용은 매우 중요합니다. 비용 절감 및 규제 당국의 지원과 같은 촉진요인은 시장 성장을 가속하는 반면, 시장 수용성 및 가격 압박과 같은 도전 요인은 신중하게 관리해야 합니다.

목차

제1장 주요 요약

제2장 세계의 트라스투주맙 바이오시밀러 시장 : 시장 역학

• 서론, 배경, 분류
• 공급망
• 업계 촉진요인과 과제

제3장 시장 동향과 예측 분석(2018년-2030년)

• 거시경제 동향(2018-2023년)과 예측(2024-2030년)
• 세계의 트라스투주맙 바이오시밀러 시장 동향(2018-2023년)과 예측(2024-2030년)
• 세계의 트라스투주맙 바이오시밀러 시장 : 제품별
  • Ogivri
  • Herzuma
  • Ontruzant
  • Trazimera
  • 기타
• 세계의 트라스투주맙 바이오시밀러 시장 : 적응증별
  • 유방암 보조 요법
  • 전이성 유방암
  • 전이성 위암
  • 기타
• 세계의 트라스투주맙 바이오시밀러 시장 : 유통 채널별
  • 병원 약국
  • 온라인 약국

제4장 지역별 시장 동향과 예측 분석(2018년-2030년)

• 세계의 트라스투주맙 바이오시밀러 시장 : 지역별
• 북미의 트라스투주맙 바이오시밀러 시장
• 유럽의 트라스투주맙 바이오시밀러 시장
• 아시아태평양의 트라스투주맙 바이오시밀러 시장
• 기타 지역의 트라스투주맙 바이오시밀러 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter의 Five Forces 분석

제6장 성장 기회와 전략 분석

• 성장 기회 분석
  • 세계의 트라스투주맙 바이오시밀러 시장 성장 기회 : 제품별
  • 세계의 트라스투주맙 바이오시밀러 시장 성장 기회 : 적응증별
  • 세계의 트라스투주맙 바이오시밀러 시장 성장 기회 : 유통 채널별
  • 세계의 트라스투주맙 바이오시밀러 시장 성장 기회 : 지역별
• 세계 트라스투주맙 바이오시밀러 시장의 새로운 동향
• 전략적 분석
  • 신제품 개발
  • 세계의 트라스투주맙 바이오시밀러 시장 생산능력 확대
  • 세계 트라스투주맙 바이오시밀러 시장의 인수합병(M&A) 및 합작투자
  • 인증 및 라이선싱

제7장 주요 기업 개요

• Pfizer
• Outlook Therapeutics
• Merck
• Amgen
• BioXpress Therapeutics
• Teva Pharmaceutical Industries
• Mylan
• Fujifilm Kyowa Kirin Biologics
• Innovent Biologics
• STADA Arzneimittel

영문목차

Trastuzumab Biosimilar Trends and Forecast

The future of the global trastuzumab biosimilar market looks promising with opportunities in the hospital pharmacy and online pharmacy markets. The global trastuzumab biosimilar market is expected to grow with a CAGR of 28.5% from 2024 to 2030. The major drivers for this market are rising rates of stomach & breast cancer and an expanding creation of biosimilar pipelines.

• Lucintel forecasts that, within the product category, ogivri is expected to witness the highest growth over the forecast period.
• Within the distribution channel category, hospital pharmacy is expected to witness higher growth over the forecast period.
• In terms of regions, North America will remain the largest region over the forecast period.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Trastuzumab Biosimilar Market

Emerging trends in the trastuzumab biosimilar market are reshaping its future applications and dynamics:

• Increased Regulatory Approvals: The surge in regulatory approvals for trastuzumab biosimilars across major markets is accelerating their adoption. This trend reflects growing confidence in the safety and efficacy of biosimilars, leading to broader market penetration.
• Cost Competitiveness: Pricing strategies are becoming increasingly competitive as more biosimilars enter the market. This trend is reducing treatment costs, making trastuzumab more accessible to a broader patient population, especially in cost-sensitive regions.
• Technological Innovations: Advances in manufacturing technologies are improving the efficiency and scalability of biosimilar production. This is lowering production costs and enhancing the quality of biosimilars, further boosting market growth.
• Global Collaborations: Strategic partnerships between biotech firms, pharmaceutical companies, and research institutions are fostering innovation and expanding the global reach of trastuzumab biosimilars. These collaborations are crucial for navigating regulatory complexities and scaling distribution.
• Patient-Centric Approaches: There is a growing emphasis on patient education and support programs to increase the acceptance of biosimilars. This trend is vital for overcoming skepticism and ensuring successful integration into standard treatment regimens.

In conclusion, these emerging trends are driving the expansion and evolution of the trastuzumab biosimilar market, making cancer treatment more accessible and affordable while maintaining high standards of care.

Recent Developments in the Trastuzumab Biosimilar Market

Ongoing innovations and advancements in the trastuzumab biosimilar market include:

• FDA Approvals: The U.S. FDA's approval of multiple trastuzumab biosimilars has significantly increased market competition, leading to lower prices and expanded access to treatment. This development is critical for broadening patient access to life-saving therapies.
• Local Production in China: China's push for domestic biosimilar production has led to the approval and commercialization of cost-effective trastuzumab biosimilars. This development is reducing reliance on imports and improving local access to oncology treatments.
• Reimbursement Integration in Germany: Germany's inclusion of trastuzumab biosimilars in national reimbursement schemes is enhancing their adoption. This ensures that patients can access these therapies under national healthcare plans, reducing out-of-pocket costs.
• Streamlined Approvals in India: India's regulatory agencies have streamlined the approval processes for biosimilars, resulting in quicker market entries for trastuzumab alternatives. This is essential for meeting the rising demand for affordable cancer therapies.
• Collaborations in Japan: Collaborative efforts between Japanese and global pharmaceutical companies are leading to the successful introduction of trastuzumab biosimilars. These partnerships are vital for navigating Japan's unique regulatory landscape and ensuring market success.

In conclusion, these developments are significantly impacting the trastuzumab biosimilar market, enhancing global access to affordable cancer treatments and driving market growth through innovation and collaboration.

Strategic Growth Opportunities for Trastuzumab Biosimilar Market

Some key strategic growth opportunities in the trastuzumab biosimilar market include:

• Expansion in Emerging Markets: Expanding trastuzumab biosimilar availability in emerging markets presents significant growth opportunities. Lower-cost alternatives are crucial in these regions, where access to expensive biologics has been limited.
• Integration into National Healthcare Systems: Incorporating trastuzumab biosimilars into national healthcare reimbursement schemes can drive adoption. This strategy is essential for increasing patient access and reducing treatment costs.
• Oncology Treatment Protocols: As trastuzumab biosimilars gain acceptance, their integration into standard oncology treatment protocols is expanding. This opportunity is broadening their use across a wider patient base.
• Innovative Pricing Strategies: Developing innovative pricing models, such as value-based pricing, can enhance market competitiveness. This approach aligns cost with therapeutic outcomes, appealing to both healthcare providers and payers.
• Strategic Partnerships: Forming strategic partnerships between biosimilar developers and large pharmaceutical firms can accelerate market penetration. These alliances are crucial for navigating regulatory environments and scaling distribution.

In conclusion, these growth opportunities are driving the expansion of the trastuzumab biosimilar market, making cancer treatment more accessible and affordable across various regions and healthcare systems.

Trastuzumab Biosimilar Market Driver and Challenges

The trastuzumab biosimilar market is shaped by various drivers and challenges, including technological, economic, and regulatory factors. These elements collectively influence market growth and the accessibility of biosimilar therapies.

Drivers of the Trastuzumab Biosimilar Market:

1. Cost Savings: The lower cost of biosimilars compared to originator biologics is driving their adoption, especially in cost-sensitive markets.

2. Patent Expirations: The expiration of patents for originator biologics is opening the market to biosimilars, increasing competition and lowering prices.

3. Regulatory Support: Favorable regulatory frameworks in key markets are accelerating the approval and adoption of biosimilars.

4. Growing Cancer Incidence: The rising incidence of cancer globally is increasing the demand for affordable treatments, boosting biosimilar market growth.

5. Advances in Biotechnology: Innovations in biotechnological processes are enhancing the production and quality of biosimilars, making them more competitive.

Challenges in the Trastuzumab Biosimilar Market:

1. Market Acceptance: Gaining physician and patient trust in biosimilars remains a challenge, requiring extensive education and clinical data.

2. Regulatory Complexities: Navigating different regulatory requirements across regions can be complex and time-consuming for biosimilar developers.

3. Pricing Pressure: Intense competition among biosimilars is driving down prices, which may affect profitability and market sustainability.

In conclusion, the interplay of these drivers and challenges is crucial in shaping the trastuzumab biosimilar market. While drivers like cost savings and regulatory support are propelling market growth, challenges such as market acceptance and pricing pressure need to be carefully managed.

List of Trastuzumab Biosimilar Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies trastuzumab biosimilar companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the trastuzumab biosimilar companies profiled in this report include-

• Pfizer
• Outlook Therapeutics
• Merck
• Amgen
• BioXpress Therapeutics
• Teva Pharmaceutical Industries
• Mylan
• Fujifilm Kyowa Kirin Biologics
• Innovent Biologics
• STADA Arzneimittel

Trastuzumab Biosimilar by Segment

The study includes a forecast for the global trastuzumab biosimilar by product, indication, distribution channel, and region.

Trastuzumab Biosimilar Market by Product [Analysis by Value from 2018 to 2030]:

• Ogivri
• Herzuma
• Ontruzant
• Trazimera
• Others

Trastuzumab Biosimilar Market by Indication [Analysis by Value from 2018 to 2030]:

• Adjuvant Breast Cancer
• Metastatic Breast Cancer
• Metastatic Gastric Cancer
• Others

Trastuzumab Biosimilar Market by Distribution Channel [Analysis by Value from 2018 to 2030]:

• Hospital Pharmacy
• Online Pharmacy

Trastuzumab Biosimilar Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Trastuzumab Biosimilar Market

Major players in the market are expanding their operations and forming strategic partnerships to strengthen their positions. Below are recent developments by major trastuzumab biosimilar producers in key regions: the USA, China, India, Japan, and Germany:

• United States: Recent FDA approvals of multiple trastuzumab biosimilars have intensified market competition, driving down prices and increasing accessibility for patients. Strategic partnerships between biotech companies and large pharmaceutical firms have accelerated market penetration.
• China: China has witnessed rapid approval and adoption of trastuzumab biosimilars, supported by government policies encouraging domestic production. The local market is expanding with a focus on affordability and access, particularly in regional cancer treatment centers.
• Germany: Germany's biosimilar market is evolving with an emphasis on integrating trastuzumab biosimilars into national healthcare reimbursement systems. Recent developments include increased clinical data supporting biosimilarity, enhancing physician confidence and patient acceptance.
• India: India has become a key player in trastuzumab biosimilar production, with several companies launching cost-competitive products. Regulatory pathways have been streamlined, facilitating quicker approvals and expanding access to affordable cancer therapies.
• Japan: In Japan, recent developments focus on the introduction of trastuzumab biosimilars through collaborations between local and international firms. The government's supportive regulatory environment is encouraging the adoption of biosimilars in oncology treatment protocols.

Features of the Global Trastuzumab Biosimilar Market

Market Size Estimates: Trastuzumab biosimilar market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Trastuzumab biosimilar market size by product, indication, distribution channel, and region in terms of value ($B).

Regional Analysis: Trastuzumab biosimilar market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different products, indications, distribution channels, and regions for the trastuzumab biosimilar market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the trastuzumab biosimilar market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the trastuzumab biosimilar market by product (ogivri, herzuma, ontruzant, trazimera, and others), indication (adjuvant breast cancer, metastatic breast cancer, metastatic gastric cancer, and others), distribution channel (hospital pharmacy and online pharmacy), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Trastuzumab Biosimilar Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Trastuzumab Biosimilar Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Trastuzumab Biosimilar Market by Product
  • 3.3.1: Ogivri
  • 3.3.2: Herzuma
  • 3.3.3: Ontruzant
  • 3.3.4: Trazimera
  • 3.3.5: Others
• 3.4: Global Trastuzumab Biosimilar Market by Indication
  • 3.4.1: Adjuvant Breast Cancer
  • 3.4.2: Metastatic Breast Cancer
  • 3.4.3: Metastatic Gastric Cancer
  • 3.4.4: Others
• 3.5: Global Trastuzumab Biosimilar Market by Distribution Channel
  • 3.5.1: Hospital Pharmacy
  • 3.5.2: Online Pharmacy

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Trastuzumab Biosimilar Market by Region
• 4.2: North American Trastuzumab Biosimilar Market
  • 4.2.1: North American Market by Product: Ogivri, Herzuma, Ontruzant, Trazimera, and Others
  • 4.2.2: North American Market by Indication: Adjuvant Breast Cancer, Metastatic Breast Cancer, Metastatic Gastric Cancer, and Others
• 4.3: European Trastuzumab Biosimilar Market
  • 4.3.1: European Market by Product: Ogivri, Herzuma, Ontruzant, Trazimera, and Others
  • 4.3.2: European Market by Indication: Adjuvant Breast Cancer, Metastatic Breast Cancer, Metastatic Gastric Cancer, and Others
• 4.4: APAC Trastuzumab Biosimilar Market
  • 4.4.1: APAC Market by Product: Ogivri, Herzuma, Ontruzant, Trazimera, and Others
  • 4.4.2: APAC Market by Indication: Adjuvant Breast Cancer, Metastatic Breast Cancer, Metastatic Gastric Cancer, and Others
• 4.5: ROW Trastuzumab Biosimilar Market
  • 4.5.1: ROW Market by Product: Ogivri, Herzuma, Ontruzant, Trazimera, and Others
  • 4.5.2: ROW Market by Indication: Adjuvant Breast Cancer, Metastatic Breast Cancer, Metastatic Gastric Cancer, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Trastuzumab Biosimilar Market by Product
  • 6.1.2: Growth Opportunities for the Global Trastuzumab Biosimilar Market by Indication
  • 6.1.3: Growth Opportunities for the Global Trastuzumab Biosimilar Market by Distribution Channel
  • 6.1.4: Growth Opportunities for the Global Trastuzumab Biosimilar Market by Region
• 6.2: Emerging Trends in the Global Trastuzumab Biosimilar Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Trastuzumab Biosimilar Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Trastuzumab Biosimilar Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Pfizer
• 7.2: Outlook Therapeutics
• 7.3: Merck
• 7.4: Amgen
• 7.5: BioXpress Therapeutics
• 7.6: Teva Pharmaceutical Industries
• 7.7: Mylan
• 7.8: Fujifilm Kyowa Kirin Biologics
• 7.9: Innovent Biologics
• 7.10: STADA Arzneimittel